TP53 and Richter syndrome: Although all three of the patients with TP53-aberrant CLL derived clinical benefit from DFCR, 2 of these patients have already progressed including 1 with Richter’s syndrome, and given the variety of active novel-agent-only regimens now available for such patients, our data do not support DFCR as a preferred option for such patients.